DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Gadgeel S. et al.
Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study.
ESMO; 2017 abstr. 1296O
Access:
We do not assume any responsibility for the contents of the web pages of other providers.